bluebird bio Inc. (NASDAQ:BLUE) shares traded -1.07% lower at $3.70 on Wall Street last session.
In accordance with the data, 13 analysts cover bluebird bio Inc. (NASDAQ:BLUE). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $3.00, we find $7.00. Given the previous closing price of $3.74, this indicates a potential upside of 87.17 percent. BLUE stock price is now -5.02% away from the 50-day moving average and -37.24% away from the 200-day moving average. The market capitalization of the company currently stands at $397.90M.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
It has been rated a hold by 8 analysts and a buy by 1. Brokers who have rated the stock have averaged $6.91 as their price target over the next twelve months.
In other news, Leschly Nick, Director sold 4,290 shares of the company’s stock on Jan 11. The stock was sold for $33,480 at an average price of $7.80. Upon completion of the transaction, the Director now directly owns 280,149 shares in the company, valued at $1.04 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 11, President and CEO Obenshain Andrew sold 3,178 shares of the business’s stock. A total of $24,802 was realized by selling the stock at an average price of $7.80. This leaves the insider owning 242,690 shares of the company worth $0.9 million. Insiders disposed of 63,901 shares of company stock worth roughly $0.24 million over the past 1 year. A total of 1.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BLUE stock. A new stake in bluebird bio Inc. shares was purchased by DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) during the first quarter worth $8,048,000. SOFINNOVA INVESTMENTS, INC. invested $2,489,000 in shares of BLUE during the first quarter. In the first quarter, ENDURANT CAPITAL MANAGEMENT LP acquired a new stake in bluebird bio Inc. valued at approximately $1,943,000. PROFUND ADVISORS LLC acquired a new stake in BLUE for approximately $1,099,000. MAVEN SECURITIES LTD purchased a new stake in BLUE valued at around $925,000 in the second quarter. In total, there are 269 active investors with 81.30% ownership of the company’s stock.
bluebird bio Inc. (NASDAQ: BLUE) opened at $3.7350 on Tuesday. During the past 12 months, bluebird bio Inc. has had a low of $2.78 and a high of $8.58. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.00, and a quick ratio of 3.00. The fifty day moving average price for BLUE is $3.8756 and a two-hundred day moving average price translates $5.8859 for the stock.
The latest earnings results from bluebird bio Inc. (NASDAQ: BLUE) was released for Mar, 2023. The company reported revenue of $2.38 million for the quarter, compared to $1.95 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 22.42 percent. For the current quarter, analysts expect BLUE to generate $11.77M in revenue.
bluebird bio Inc.(BLUE) Company Profile
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company’s clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
Leave a Reply